GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Current Deferred Revenue

Curocell (XKRX:372320) Current Deferred Revenue : ₩0.00 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Curocell's current deferred revenue for the quarter that ended in Jun. 2023 was ₩0.00 Mil.

Curocell Current Deferred Revenue Historical Data

The historical data trend for Curocell's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Current Deferred Revenue Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - - -

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue - - - -

Curocell Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Curocell's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Curocell (XKRX:372320) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines